Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia

World J Gastroenterol. 2014 Apr 21;20(15):4421-7. doi: 10.3748/wjg.v20.i15.4421.

Abstract

Aim: To investigate the expression and prognostic value of CCL2 in gastric cancer, as well as its relationship with tumor hypoxia.

Methods: Tumor tissues from 68 gastric cancer patients (GC) were analyzed, and the expression of CCL2 and hypoxia-inducible factor 1 alpha (HIF-1α) in tumor tissues was detected by immunohistochemistry. Statistical evaluations that were used included univariate log-rank tests of Kaplan-Meier curves and multivariate Cox regression model analysis.

Results: CCL2 was highly expressed in 66.2% (45/68) of gastric cancer specimens. The distribution of CCL2 expression in tumor tissue was consistent with that of HIF-1α. Patients with high CCL2 expression in GC had a lower overall survival rate [50.6 mo (95%CI: 44.44-56.93) vs 64.6 mo (95%CI: 60.27-68.94), P = 0.013].

Conclusion: CCL2 expression correlates closely with HIF-1α expression in gastric cancer. CCL2 may be an independent prognostic marker for GC.

Keywords: Chemokines; Gastric cancer; Immunohistochemistry; Monocyte chemotactic protein-1/CCL2; Prognostic marker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma / metabolism*
  • Chemokine CCL2 / metabolism*
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Hypoxia
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism*
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Stomach Neoplasms / metabolism*
  • Treatment Outcome

Substances

  • CCL2 protein, human
  • Chemokine CCL2
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit